Relmada Therapeutics (RLMD) Akcija Цена

Relmada Therapeutics Цена

NASDAQ·ZATVORENO
2,91
​
Tržište je zatvoreno

Prihod Relmada Therapeutics opadao je 28,4 % godišnje u poslednjih 2 godina na 5.129,00 USD. Za Relmada Therapeutics neto marža od -877,7 % je pala u odnosu na -100,0 % pre nekoliko godina. Konsenzusna 12-mesečna ciljana cena za Relmada Therapeutics je 11,00 USD, oko iznad kurs za 278,0 %. Od 10 analitičara 9 preporučuje kupovinu — ukupni konsenzus je Kupi.

Cena akcije Relmada Therapeutics

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Relmada Therapeutics poslovni model i analiza akcije

Relmada Therapeutics Inc je biofarmaceutska kompanija specijalizovana za razvoj lekova za razne hronične bolove i mentalne zdravstvene poremećaje. Kompanija ima sedište u Njujorku, SAD, i osnovana je 2004. godine. Istorija Relmada Therapeutics Inc-a počinje sa fokusom na razvoj antagonista NMDA receptora za lečenje neuropatskog bola. Glavni lek kompanije, d-Methadone, uspešno je testiran u kliničkoj studiji faze IIa i sada se testira u studijama faze IIb. Poslovni model Relmada Therapeutics Inc-a zasnovan je na razvoju i komercijalizaciji novih lekova koji ciljaju na visoke medicinske potrebe. Kompanija poseduje jak portfolijo farmaceutskih proizvoda u različitim kliničkim fazama koji se mogu koristiti u upravljanju bolom i promociji mentalnog zdravlja. Relmada Therapeutics Inc ostvaruje prihode kroz prodaju patenata i izdavanje licenci za svoje proizvode drugim farmaceutskim kompanijama. Pored toga, kompanija teži partnerstvima i zajedničkim ulaganjima sa drugim kompanijama kako bi dalje razvila i plasirala svoje proizvode. Relmada Therapeutics Inc posluje u tri glavna odeljenja: terapija bola, mentalno zdravlje i onkologija. U terapiji bola, kompanija ima svoje glavne proizvode, kao što su Oral Methadone i LevoCap ER, koji pomažu pacijentima da ublaže hronični bol. LevoCap ER je dugotrajni, ne-narkotički lek protiv bola koji povećava efikasnost i bezbednost u poređenju sa drugim opioidima. U oblasti mentalnog zdravlja, Relmada Therapeutics Inc je razvio QN-19, blokator hiperaktivnih NMDA receptora, koji predstavlja potencijalnu opciju lečenja za depresivne poremećaje. Kompanija je takođe razvila svoju novu tehnološku platformu mGluR2/3 agonista, koja se može koristiti u lečenju anksioznosti i depresije. U odeljenju za onkologiju, kompanija se fokusira na razvoj inovativnih tretmana za rak. Trenutno razvija novi lek za rak koji cilja na prevazilaženje rezistencije na hemoterapiju. Relmada Therapeutics Inc je posvećen pružanju inovativnih rešenja za poboljšanje kvaliteta života pacijenata. Kompanija se oslanja na snažnu platformu za istraživanje i razvoj kako bi razvila lekove koji ciljaju na razne potrebe. Kompanija je posvećena nastavku svog istraživanja i razvoja kako bi pružila inovativna rešenja koja poboljšavaju lečenje hroničnih bolesti.

Često postavljana pitanja o akciji Relmada Therapeutics

Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.

Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.

Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.

Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.

Relmada Therapeutics Inc primarily operates in the United States.

Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.

Analitičari trenutno postavljaju prosečnu ciljanu cenu 11,00 USD za akciju Relmada Therapeutics (medijana: 11,00 USD), što znači +278,0 % u odnosu na poslednju cenu. Konsenzus se zasniva na 10 ocena.

10 analitičara trenutno ocenjuje akciju Relmada Therapeutics: 9 preporučuje kupovinu, 1 držanje i 0 prodaju.

Po trenutnom kursu akcija Relmada Therapeutics kotira 2,65 EUR (2,91 USD).

Akcija Relmada Therapeutics (RLMD) kotira na 3 berze, uključujući: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).

Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.

Prihod se trenutno ne može izračunati za Relmada Therapeutics.

očekivana dobit od Relmada Therapeutics je -12,37 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za Relmada Therapeutics je trenutno -16,06. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije Relmada Therapeutics.

KUV se trenutno ne može izračunati za Relmada Therapeutics.

Eulpool score kvaliteta za Relmada Therapeutics je 2/10.

ISIN za Relmada Therapeutics je US75955J4022. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za Relmada Therapeutics je A2PSZF. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za Relmada Therapeutics je RLMD. Simbol tikera se koristi za trgovinu akcijama Relmada Therapeutics na berzanskom tržištu.

Фер вредностTerminal
2,68 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Фармацеутски производи
Број акција
Запослени
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт relmada.com
Валута
USD
Јавна понуда
3. мар 2014.
ISIN
US75955J4022
CUSIP
75955J402
SEDOL
BK71LV3
Тржишна капитализација
87,78 М USDMicro Cap
Опсег од 52 недеље
AAQS
2 / 10
PEG
-4,80
P/E однос
P/Ee 2026
-16,06
P/Ee 2027
-16,06
P/Ee 2028
-8,90
P/Ee 2029
-7,98
P/Ee 2030
-15,49
P/S
P/Se
—
EV/EBIT
—
P/B однос
1,01
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-66,33 %
Zadnje ažurirano 19. нов 2026. 19:23

Relmada Therapeutics Тикер

FRANKFURT · 4E2.FMINHEN · 4E2.MUNASDAQ · RLMD

Relmada Therapeutics FIGI

RLMD:US · BBG003MKSL16RLMD:UA · BBG003MKSL52RLMD:UC · BBG003MKSL70RLMD:UN · BBG003MKSL98RLMD:UP · BBG003MKSLB5RLMD:UB · BBG003MKSLD3RLMD:UM · BBG003MKSLG0RLMD:UX · BBG003MKSLH9RLMD:UD · BBG003MKSLP0RLMD:UW · BBG003MKSLR8RLMD:UF · BBG003MKSLS7RLMD:VY · BBG003MKSLT6